BACKGROUND: Lung cancer has progressively become a disease of older people, with the median age at diagnosis now exceeding 70 years. Octogenarians represent a rapidly growing proportion of patients diagnosed with lung cancer and can present distinct challenges. Nevertheless, current literature that has set the evidence-based standards of care in this disease does not include significant numbers of patients older than 80 years. METHODS: We have compiled and reviewed the available literature on the specific management and treatment of lung cancer in patients older than 80 years. RESULTS: Retrospective series suggest that surgery is safe and effective in treating early-stage non-small cell lung cancer in selected patients older than 80 years. There is minimal data to support the use of adjuvant chemotherapy in this group. In addition, no data exist on the use of combined chemotherapy and radiotherapy for locally advanced disease. In advanced or metastatic disease, similar to younger elderly populations, single-agent chemotherapy is feasible and seems to offer benefit in terms of symptoms and outcomes. Small cell lung cancer in this population is not well characterized, but small studies suggest symptom improvement and prolongation of survival with the use of chemotherapy. CONCLUSION: Based on retrospective series, octogenarians with lung cancer can derive benefit from many of the treatment modalities used for younger patients including surgery for early-stage disease and single-agent chemotherapy for advanced disease. More elderly specific trials are needed to better refine treatment decisions and improve the care of lung cancer in this group.
BACKGROUND:Lung cancer has progressively become a disease of older people, with the median age at diagnosis now exceeding 70 years. Octogenarians represent a rapidly growing proportion of patients diagnosed with lung cancer and can present distinct challenges. Nevertheless, current literature that has set the evidence-based standards of care in this disease does not include significant numbers of patients older than 80 years. METHODS: We have compiled and reviewed the available literature on the specific management and treatment of lung cancer in patients older than 80 years. RESULTS: Retrospective series suggest that surgery is safe and effective in treating early-stage non-small cell lung cancer in selected patients older than 80 years. There is minimal data to support the use of adjuvant chemotherapy in this group. In addition, no data exist on the use of combined chemotherapy and radiotherapy for locally advanced disease. In advanced or metastatic disease, similar to younger elderly populations, single-agent chemotherapy is feasible and seems to offer benefit in terms of symptoms and outcomes. Small cell lung cancer in this population is not well characterized, but small studies suggest symptom improvement and prolongation of survival with the use of chemotherapy. CONCLUSION: Based on retrospective series, octogenarians with lung cancer can derive benefit from many of the treatment modalities used for younger patients including surgery for early-stage disease and single-agent chemotherapy for advanced disease. More elderly specific trials are needed to better refine treatment decisions and improve the care of lung cancer in this group.
Authors: Gregory J Britt; Elizabeth M Gaughan; Kim-Son H Nguyen; Jeremy L Warner; Michael A Goldstein; Mark S Huberman; Daniel B Costa Journal: J Thorac Dis Date: 2011-06 Impact factor: 2.895
Authors: Ming-Ching Lee; Daniel H Buitrago; Kyuichi Kadota; Hideki Ujiie; Kaitlin Woo; Camelia S Sima; William D Travis; David R Jones; Prasad S Adusumilli Journal: Oncoimmunology Date: 2014-12-21 Impact factor: 8.110
Authors: Marjorie G Zauderer; Camelia S Sima; Beatriz Korc-Grodzicki; Mark G Kris; Lee M Krug Journal: J Geriatr Oncol Date: 2013-01 Impact factor: 3.599